School of Chinese Medicine, The University of Hong Kong, Hong Kong S.A.R., China.
Centre for Chinese Herbal Medicine Drug Development, School of Chinese Medicine, Hong Kong Baptist University, Hong Kong S.A.R., China.
Int J Biol Sci. 2023 Oct 16;19(16):5257-5274. doi: 10.7150/ijbs.87327. eCollection 2023.
A high postoperative tumour recurrence rate has significantly rendered a poorer prognosis in hepatocellular carcinoma (HCC) patients. The aim of this study is to identify a natural compound genipin as a potential and effective candidate to suppress the postoperative recurrence of HCC. Clinical analysis revealed that infiltration of macrophage into the adjacent tissue but not HCC predicted patients' poor prognosis on recurrence-free survival. Genipin intervention suppressed the Ly6C+CD11b+F4/80+ pro-inflammatory macrophage infiltration in the postoperative liver of mice. Adoptive transfer of pro-inflammatory monocytic cells completely abolished the inhibitory effect of genipin on HCC recurrence. Transcriptomic analysis on FACs-sorted macrophages from the postoperative livers of mice revealed that PPARγ signalling was involved in the regulatory effect of genipin. Genipin is directly bound to PPARγ, causing PPARγ-induced p65 degradation, which in turn suppressed the transcriptional activation of CCR2 signalling. PPARγ antagonist GW9662 abrogated the effects of genipin on CCR2-medaited macrophage infiltration as well as HCC recurrence. Cytokine array analysis identified that genipin intervention potently suppressed the secretion of CCL2 further partially contributed to the pro-inflammatory macrophage infiltration into the postoperative liver. Multiplex immunostaining on tissue array of human HCC revealed that PPARγ expression was inversely associated with CCL2 and the macrophage infiltration in the adjacent liver of HCC patients. Our works provide scientific evidence for the therapeutic potential of genipin as a PPARγ agonist in preventing postoperative recurrence of HCC.
高术后肿瘤复发率显著降低了肝细胞癌(HCC)患者的预后。本研究旨在鉴定一种天然化合物京尼平作为抑制 HCC 术后复发的潜在有效候选物。临床分析表明,巨噬细胞浸润到相邻组织中,而不是 HCC,预测患者无复发生存率的预后不良。京尼平干预抑制了小鼠术后肝脏中 Ly6C+CD11b+F4/80+促炎性巨噬细胞的浸润。促炎性单核细胞的过继转移完全消除了京尼平对 HCC 复发的抑制作用。对从小鼠术后肝脏中 FACs 分选的巨噬细胞进行转录组分析表明,PPARγ信号通路参与了京尼平的调节作用。京尼平直接与 PPARγ结合,导致 PPARγ诱导的 p65 降解,从而抑制了 CCR2 信号的转录激活。PPARγ拮抗剂 GW9662 消除了京尼平对 CCR2 介导的巨噬细胞浸润以及 HCC 复发的影响。细胞因子阵列分析表明,京尼平干预强烈抑制了 CCL2 的分泌,这在一定程度上导致了促炎性巨噬细胞浸润到术后肝脏。对人 HCC 组织芯片的多重免疫染色表明,PPARγ表达与 HCC 患者相邻肝组织中的 CCL2 和巨噬细胞浸润呈负相关。我们的工作为京尼平作为 PPARγ激动剂在预防 HCC 术后复发方面的治疗潜力提供了科学证据。